Navigation Links
Jon M. Huntsman Receives American Cancer Society Medal of Honor
Date:11/21/2008

THE WOODLANDS, Texas, Nov. 21 /PRNewswire-FirstCall/ -- Huntsman Corporation (NYSE: HUN) today announced that its Founder and Chairman, Jon M. Huntsman, is one of four Americans chosen by the American Cancer Society to receive this year's Medal of Honor, its highest honor. Given annually, the award is reserved for those who have made outstanding contributions to the fight against cancer.

Noting that Mr. Huntsman and his wife Karen Huntsman have "raised or personally contributed over $600 million to the fight against cancer," the American Cancer Society awarded Mr. Huntsman its Medal of Honor for the category of Cancer Philanthropy.

Huntsman Corporation's President and CEO Peter Huntsman observed, "I and the many thousands of other associates that work for Huntsman Corporation around the globe are immensely proud that our Chairman has chosen to return to society so much of his personal gain from the success of our company."

About Huntsman:

Huntsman is a global manufacturer and marketer of differentiated chemicals. Its operating companies manufacture products for a variety of global industries, including chemicals, plastics, automotive, aviation, textiles, footwear, paints and coatings, construction, technology, agriculture, health care, detergent, personal care, furniture, appliances and packaging. Originally known for pioneering innovations in packaging and, later, for rapid and integrated growth in petrochemicals, Huntsman today has 13,000 employees and operates from multiple locations worldwide. The Company had 2007 revenues of approximately $10 billion. For more information about Huntsman, please visit the company's website at http://www.huntsman.com.

Forward-Looking Statements:

Statements in this release that are not historical are forward-looking statements. These statements are based on management's current beliefs and expectations. The forward-looking statements in this release are subject to uncertainty and changes in circumstances and involve risks and uncertainties that may affect the company's operations, markets, products, services, prices and other factors as discussed in the Huntsman companies' filings with the U.S. Securities and Exchange Commission. Significant risks and uncertainties may relate to, but are not limited to, financial, economic, competitive, environmental, political, legal, regulatory and technological factors. In addition, the completion of any transactions described in this release is subject to a number of uncertainties and closing will be subject to approvals and other customary conditions. Accordingly, there can be no assurance that such transactions will be completed or that the company's expectations will be realized. The company assumes no obligation to provide revisions to any forward-looking statements should circumstances change, except as otherwise required by applicable laws.


'/>"/>
SOURCE Huntsman Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Honorable Edward M. Kennedy, Scientists Mina J. Bissell and Susan Band Horwitz, and Philanthropist Jon M. Huntsman to Receive American Cancer Society Highest Honor for Outstanding Contributions to Cancer Fight
2. Huntsman to Discuss Fourth Quarter and Full Year 2007 Results on Friday, February 22, 2008
3. Keryx Biopharmaceuticals Receives Nasdaq Notification
4. Kaiser Permanente Receives the Most Stars in California Office of Patient Advocates Annual Quality Report Card
5. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
6. Naviscan Receives 510(k) Clearance for Stereo Navigator(TM) - the First Commercially Available Breast PET-Guided Biopsy Feature
7. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
8. Capital BlueCross Receives Prestigious Corporation of the Year Award
9. Bmc nurse manager receives Abstract Award
10. Cancer researcher receives $3.8 million award from US Department of Defense
11. Virginia Mental Health Hospital Improves Patient Comfort, Receives Award for Energy-Saving Renovations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... ... Outlook’s top Clinical Data Management Solution Providers list for its expertise in eClinical ... and domain expertise to serve the technology needs of global clients. DDi provides ...
(Date:2/12/2016)... Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick ... fact a love story, the love of a Buddhist teacher for teaching and helping ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce ... from U.S. universities who will draw from Siemens’ deep knowledge of product ...
(Date:2/12/2016)... ... ... , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – 12:30 p.m. ... learn from history are doomed to repeat it.” , An analysis of CDRH’s enforcement actions ... takes time. , Take a close look at the warning letters the agency sent ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Each year, the ... be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists ... new therapy products in action, learn more about their chosen field and network with ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  SI-BONE, Inc., a medical device company that ... a minimally invasive surgical (MIS) device indicated for fusion for certain ... Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states of ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
Breaking Medicine Technology: